PeptideWellness
Take the quiz
§ By goal
§ Most read
Featured · field guide
The 2026 GLP-1 telehealth field guide.

Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.

Read the guide
§ The providers
Who sells what — and who to trust.

An independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.

View the provider overviewAll 17 reviews
§ Learn
The educational layer, in progress.

Primers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.

View all Learn articles
§ Interactive tools
60-second quiz PeptideMatch Start here Answer four questions, get a goal-matched protocol and provider. The record GLP-1 price history Every price change we have recorded, with the figure before and after it. Overview All tools The full tools page — quiz, the Index, its history, and how we build them. Method How we measure a price What counts as the price, where we read it, and how often it is re-checked.
Free to use Medically reviewed methodology How we build our tools
PeptideWellness Index
The GLP-1 Price Index

What compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.

See the full index
Independent clinical intelligence

Peptide therapeutics for clinical practice.

Independent intelligence for functional-medicine physicians, anti-aging clinics, and compounding-pharmacy buyers — pharmacy comparisons, clinical references, and regulatory tracking.

Compare compounding pharmaciesTrack the regulatory picture
Editorially independentNo paid placementSources cited inline
§ Two ways in

Choose your path.

For clinics & physicians

Dosing references, clinical protocols, and source-cited evidence.

Evidence-graded references and protocol summaries built for prescribers.

Resources for clinics →For compounding-pharmacy buyers

Compare accredited 503A compounders, side by side.

Side-by-side reads on accredited 503A/503B compounders — capabilities, accreditation, and what to look for.

Compare pharmacies →

Editorial independence We take no payment for coverage, placement or rankings, and we publish corrections. Editorial policy

§ The zone

What's inside.

Pharmacy intelligence

Compounding pharmacies

Compare accredited 503A/503B compounders, side by side.

Explore →Clinical

Dosing & protocols

Dosing references and protocol summaries for prescribers.

Explore →Regulatory & research

Regulatory tracking

503A/503B changes and compounding policy, with dates.

Explore →Whitepapers

Field reports

Independent field reports — in production, not yet available.

See what's coming →
In preparation
Field report · in production

State of Compounded Peptides 2026

A field report for prescribers and pharmacy buyers, in production now. What it will cover:

  • Where 503A/503B supply actually stands after the 2025 shortage delistings.
  • Median compounded GLP-1 pricing by channel, with margin context for buyers.
  • What the July 2026 PCAC vote changed for the seven peptides it covered — and what it didn't.

Not available yet, and we're not collecting email addresses for it until it is. In the meantime, the underlying material is published in full: the compounding-pharmacy directory, the price Index, and our regulatory reporting.

PeptideWellness Weekly Pro

A Saturday digest for peptide professionals — in preparation.

Regulatory moves, compounding-supply shifts, and clinical references, written for prescribers and buyers rather than patients. It isn't running yet, so there's nothing to sign up for — we'd rather say that than take your address and sit on it. Everything that will go into it is already published as it happens in News and Regulatory updates.